Technology | Implantable Cardioverter Defibrillator (ICD) | August 09, 2016

FDA Clears MRI-safe Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System

Approval grants MR-conditional labeling to all Emblem S-ICD systems, expands Boston Scientific’s ScienticImageReady portfolio

S-ICD, subcutaneous implantable cardioverter defibrillator, MRI safe ICD, Emblem
FDA Clears MRI-safe Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) System

August 9, 2016 — The U.S. Food and Drug Administration (FDA) granted market approval for the Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance (MR) conditional labeling for all previously implanted Emblem S-ICD Systems. 

The new Emblem MRI S-ICD System is the latest addition to the Boston Scientific's growing line of ImageReady MR-conditional electrophysiology devices, which allow patients to undergo magnetic resonance imaging (MRI) safely.

The Emblem S-ICD system is a treatment option for patients at risk of sudden cardiac arrest, that leaves the heart and vasculature untouched, thus reducing the risk of complications associated with conventional transvenous ICD leads.

 

Watch the video, "How to Install a Subcutaneous ICD System." 
 

In addition to MR-conditional labeling, the device introduces two new features to the market – SMART Pass technology and Atrial Fibrillation (AF) Monitor. The SMART Pass technology, also being added to previously implanted Emblem S-ICD systems through a software update, increases the accuracy of the INSIGHT Algorithm to help ensure patients receive appropriate therapy from the device only when necessary. The AF Monitor feature is a detection tool designed to alert physicians after the identification of AF so they can make more informed treatment decisions for their patients.

Earlier this year, the company received FDA approval for the ImageReady MR-Conditional Pacing system, which includes Accolade MRI and Essentio MRI pacemakers, as well as Ingevity MRI pacing leads, designed to treat bradycardia. Patients implanted with the full system are able to receive full-body MR scans in a 1.5 Tesla environment when conditions of use are met. Additionally, the company is actively pursuing MRI compatibility for their currently approved implanted cardiac defibrillation and cardiac resynchronization therapy systems via the global ENABLE MRI study.

Boston Scientific received CE mark for the Emblem MRI S-ICD system earlier this year and began commercialization in Europe in June.

For more information: www.bostonscientific.com/sicd


Related Content

News | Atrial Fibrillation

March 29, 2025 — Anthos Therapeutics, Inc., presented two new analyses from its AZALEA-TIMI 71 study at the American ...

Home March 31, 2025
Home
News | Atrial Fibrillation

Broward Health recently announced it is now offering the Farapulse Pulsed Field Ablation System to treat atrial ...

Home March 12, 2025
Home
News | Atrial Fibrillation

March 1, 202 — One in three people worldwide will develop a potentially life-threatening heart rhythm disorder in their ...

Home March 03, 2025
Home
News | Atrial Fibrillation

Feb. 14, 2025 — Volta Medical, a health technology company developing artificial intelligence (AI) solutions to assist ...

Home February 14, 2025
Home
News | Atrial Fibrillation

Feb. 12, 2025 — On Feb. 11, 2025, at HonorHealth Research Institute, Rahul Doshi, M.D., cardiac electrophysiologist ...

Home February 12, 2025
Home
News | Atrial Fibrillation

Jan. 16, 2025 — Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac ...

Home January 29, 2025
Home
News | Atrial Fibrillation

Jan. 22, 2025 – Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies to treat ...

Home January 24, 2025
Home
News | Atrial Fibrillation

Dec. 19, 2024 — Drinking multiple cups of coffee a day may help prevent cognitive decline in people with atrial ...

Home December 19, 2024
Home
News | Atrial Fibrillation

Nov. 18, 2024 — Abbott recently announced new data for the Amplatzer Amulet Left Atrial Appendage (LAA) Occluder to ...

Home November 19, 2024
Home
News | Atrial Fibrillation

Oct. 18, 2024 — The Heart Rhythm Society (HRS) Board of Trustees unanimously approved the formation of Heart Rhythm ...

Home October 21, 2024
Home
Subscribe Now